Therefore, based on novel diagnosis and prognosis classifications of AML, patients with in–frame mutations in basic leucine zipper domain of CEBPA (CEBPA bZIP) were assessed as a biological AML subgroup (1.2%). This evidence concerns the gene CEBPA and acute myeloid leukemia.